ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease

Core Insights - ProMIS Neurosciences Inc. has initiated a Phase 1b clinical trial (PRECISE-AD) for its lead therapeutic candidate PMN310, targeting Alzheimer's disease [1][4] - PMN310 is a humanized IgG1 antibody designed to selectively target toxic oligomers of amyloid-beta, potentially reducing the risk of amyloid-related imaging abnormalities (ARIA) [2][4] - The trial will involve 100 patients with mild cognitive impairment or early Alzheimer's, assessing safety, tolerability, and pharmacokinetics over 12 months [3][4] Company Overview - ProMIS Neurosciences is focused on developing antibody therapeutics for neurodegenerative diseases, utilizing a proprietary platform to identify disease-specific epitopes [7] - PMN310 is designed to bind specifically to toxic amyloid-beta oligomers, which are believed to drive Alzheimer's disease progression [5][7] - The company has completed a Phase 1a study demonstrating a favorable safety profile and is now advancing to Phase 1b [6][7] Clinical Trial Details - The PRECISE-AD trial is a randomized, double-blind, placebo-controlled study evaluating multiple ascending doses of PMN310 [4] - The study will monitor safety, tolerability, pharmacokinetics, and biomarkers, with assessments every three months and frequent MRI scans to check for ARIA [4][3] - Interim data from the trial is expected in the first half of 2026 [4]